Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Aurisco Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	736.6	769.44	545.84	391.74	444.61	564.1
Trading Asset Securities	251.42	299.83	-	-	-	-
Cash & Short-Term Investments	988.03	1,069	545.84	391.74	444.61	564.1
Cash Growth	85.17%	95.89%	39.34%	-11.89%	-21.18%	112.82%
Accounts Receivable	394.12	350.87	290.78	222.11	140.72	142.85
Other Receivables	4.15	4.23	8.31	3.9	6.19	3.91
Receivables	398.27	355.11	299.09	226.01	146.91	146.76
Inventory	614.82	589.72	509.8	444.94	326.8	237.79
Prepaid Expenses	-	-	-	0.17	-	-
Other Current Assets	21.16	32.7	11.31	25.5	21.48	29.12
Total Current Assets	2,022	2,047	1,366	1,088	939.8	977.76
Property, Plant & Equipment	1,536	1,497	878.33	674.18	593.26	490.35
Long-Term Investments	133.47	133.47	79.3	55.3	15.3	0.3
Other Intangible Assets	160.28	161.46	121.4	122.71	40.42	41.94
Long-Term Deferred Tax Assets	17.04	15.78	14.29	15.24	8.56	6.3
Long-Term Deferred Charges	6.56	5.32	6.91	11.37	-	-
Other Long-Term Assets	21.31	17.41	108.35	68.14	124.09	16.56
Total Assets	3,897	3,877	2,575	2,035	1,721	1,533
Accounts Payable	274.48	297.39	242.53	102.43	128.2	97.05
Accrued Expenses	33.23	121.64	92.89	51.95	40.89	23.13
Short-Term Debt	40.03	20.02	40.04	30	-	-
Current Portion of Long-Term Debt	-	-	-	1.3	-	-
Current Portion of Leases	6.71	5.64	5.14	4.93	4.06	-
Current Income Taxes Payable	29.8	25	16.64	12.85	8.61	16.94
Current Unearned Revenue	1.69	6.6	22.25	0.98	8.96	1.93
Other Current Liabilities	51.93	55.74	81.53	117.75	2.36	2.57
Total Current Liabilities	437.87	532.04	501.02	322.17	193.08	141.61
Long-Term Debt	913.97	907.09	60.46	4.22	-	-
Long-Term Leases	12.37	15.1	11.24	12.23	13.91	-
Long-Term Unearned Revenue	92.07	91.57	34.02	7.69	4.53	4.14
Long-Term Deferred Tax Liabilities	0.19	0.1	0.28	4.81	1.92	2.23
Total Liabilities	1,456	1,546	607.03	351.13	213.44	147.98
Common Stock	406.2	406.2	406.2	406.2	401	401
Additional Paid-In Capital	608.88	606.5	584.93	553.36	491.73	489.87
Retained Earnings	1,361	1,241	975.92	751.49	592.71	472.12
Treasury Stock	-37.79	-22.86	-45.72	-57.15	-	-
Comprehensive Income & Other	102.52	100.34	46.25	22.28	20.8	22.24
Total Common Equity	2,441	2,332	1,968	1,676	1,506	1,385
Minority Interest	-	-	-	7.99	1.75	-
Shareholders' Equity	2,441	2,332	1,968	1,684	1,508	1,385
Total Liabilities & Equity	3,897	3,877	2,575	2,035	1,721	1,533
Total Debt	973.08	947.85	116.88	52.69	17.97	-
Net Cash (Debt)	14.95	121.42	428.95	339.05	426.64	564.1
Net Cash Growth	-96.11%	-71.69%	26.52%	-20.53%	-24.37%	112.82%
Net Cash Per Share	0.04	0.30	1.05	0.84	1.06	1.51
Filing Date Shares Outstanding	406.2	406.2	406.2	406.2	401	401
Total Common Shares Outstanding	406.2	406.2	406.2	406.2	401	401
Working Capital	1,584	1,515	865.02	766.19	746.72	836.15
Book Value Per Share	6.01	5.74	4.84	4.13	3.76	3.45
Tangible Book Value	2,280	2,170	1,846	1,553	1,466	1,343
Tangible Book Value Per Share	5.61	5.34	4.55	3.82	3.66	3.35
Buildings	-	291.81	291.85	289.74	283.37	277.72
Machinery	-	735.79	640.39	587.27	485.03	316.43
Construction In Progress	-	869.74	280.64	79.93	47.83	90.65

Source: S&P Global Market Intelligence. Standard template. Financial Sources.